Skip to main content

Table 4 Estimate of the resource costs for the entire cohort and of the PS-matched cohort over the study period (€/per patient/12 weeks)

From: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma

 

Overall cohort (Euro)

PS-matched cohort (Euro)

 

Group A

Group B

Difference Group B – Group A

p

Group A

Group B

Difference Group B – Group A

p

Cost of GP visits mean (±SE)

12.79 (±1.43)

5.68 (±1.77)

-7.11

<0.001

12.88 (±2.27)

5.68 (±1.77)

-7.20

<0.001

Cost of specialist visits mean (±SE)

13.68 (±1.60)

5.68 (±1.48)

-8.00

<0.001

13.95 (±2.27)

5.68 (±1.48)

-8.26

0.002

Cost of hospitalization mean (±SE)

274.55 (±82.76)

172.65 (±98.18)

-101.90

0.396

345.30 (±133.23)

172.65 (±98.18)

-172.65

0.98

  1. Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
  2. Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
  3. GP general practitioner, [95 % CI confidence interval], p refers to Wilcoxon rank-sum test